Biotech News
Prelude Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
investors.preludetx.com2026-05-06 15:00 EST
Lead candidate from mutant selective JAK2V617F JH2 inhibitor program advancing with IND filing expected in the first quarter of 2026 Lead candidate from oral KAT6A selective degrader program advancing with IND filing expected in mid-2026 Preclinical data from JAK2V617F JH2 inhibitor program and